MediWound(MDWD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, down from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [10][11] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% of revenue) in the prior year [10][11] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [12] - Net loss for 2025 was $23.9 million ($2.10 per share), improved from a net loss of $30.2 million ($3.03 per share) in 2024 [13] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE Phase III study [10][11] - SG&A expenses for Q4 2025 totaled $3.6 million, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [11] - Operating loss for the year was $25.3 million, compared to $19.4 million in 2024, indicating increased investment in R&D [12] Market Data and Key Metrics Changes - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold to meet growing global demand [8] - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing a significant portion of Vericel's target accounts [9] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for its expanded facility, focusing on long-term value creation [16] - MediWound has reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of War [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges while maintaining focus on clinical milestones and commercial objectives [5] - The company anticipates a significant increase in revenues in the second half of 2026, driven by manufacturing capacity and BARDA revenue [83] Other Important Information - The company has completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, enhancing its financial flexibility [15] - The EscharEx clinical program is expanding to include diabetic foot ulcers and pressure ulcers, with studies expected to begin in the second half of 2026 [7][8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - Management indicated that the expanded manufacturing facility is operational, with regulatory approvals expected in late 2026, which will allow for market release of products manufactured during the validation process [19][20] Question: Can you discuss the pressure ulcer trial and its market potential? - Management acknowledged that pressure ulcers represent a significant market opportunity and that the upcoming investigator-led study will help assess the potential for EscharEx in this indication [27][28] Question: What is the status of BARDA and Department of War collaborations? - Management confirmed ongoing collaboration with BARDA and the Department of War, with expectations for continued funding and support for NexoBrid development [34] Question: How does the company plan to approach the head-to-head study? - The head-to-head study against collagenase is planned to support future market access discussions, with a start date anticipated in mid-2026 [70] Question: What is the expected revenue guidance for 2026? - Management expressed confidence in achieving the revenue guidance of $24 million-$26 million, although specific splits between sources were not disclosed [48]